3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Conditions
Lung Neoplasms
1
Carcinoma, Squamous Cell
1
Carcinoma, Non-Small-Cell Lung
1
Carcinoma, Large Cell
1
Carcinoma
1
Adenocarcinoma
1
Interventions
selpercatinib
2
binimetinib
2
Crizotinib
2
ulixertinib
1
tremelimumab
1
trastuzumab biosimilar HLX02
1
trametinib
1
sapanisertib
1
repotrectinib
1
relatlimab
1
pralsetinib
1
pertuzumab
1
palbociclib
1
osimertinib
1
omipalisib
1
larotrectinib
1
ipatasertib
1
erdafitinib
1
encorafenib
1
durvalumab
1
defactinib
1
dabrafenib
1
copanlisib
1
ceritinib
1
capmatinib
1
capivasertib
1
brigatinib
1
adavosertib
1
X-Rays
1
Trastuzumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Has announcements
×
Lung Neoplasms
×
brigatinib
×
Clear all
NCT02737501
2021-08-20
ALTA-1L
Takeda
Phase 3
Completed
275 enrolled
23 charts
1 FDA